Portfolio Companies

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on serious illness. They are focused on tackling the next frontier in cancer treatment, solid tumors.

Abcuro, Inc. is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of T and NK cells that express KLRG1 (killer cell lectin like receptor G1).

Allakos, Inc. (NASDAQ: ALLK) is a clinical-stage company developing antibodies that target receptor molecules present on the surface of immune effector cells involved in allergy, inflammation, tissue damage and proliferative disorders.

Arcellx, Inc. is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Company’s vision is to expand access to cell therapies to millions of patients under the care of academic and community practices.

Atreca, Inc. (NASDAQ:  BCEL) is a biopharmaceutical company developing novel therapeutics based on a deep understanding of the human immune response.

Autobahn Labs accelerates the translation of novel science to realize the potential of academic research. 

Developing Treatments for Advanced Stage Blindness

Bolt Biotherapeutics, Inc (NASDAQ:  BOLT). is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems.

CARGO, launched by Samsara in partnership with CAR T pioneers, is advancing a clinically validated CD22 CAR T for lymphoma.

Centessa Pharmaceuticals (NASDAQ:  CNTA) aims to improve R&D productivity by scaling the asset-centric model with a deconstructed R&D environment that prioritizes data driven decision making led by subject matter experts.

Chinook Therapeutics, Inc. is a biotechnology company developing precision medicines for kidney diseases.

Decibel Therapeutics, Inc. (NASDAQ:  DBTX) is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine.

Delfi is developing a revolutionary test using DNA in the blood for early detection of cancer.  The ultimate target audience are doctors and their patients who will need this testing.

Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, to pave the way for new approaches to treating the toughest diseases.

Elevatebio is creating and operating a portfolio of cell and gene therapy companies to develop, manufacture and commercialize life-transforming medicines.

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth.

Formerly known as Ervaxx, Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population.

Fluent BioSciences is a "single cell" technology company that offers molecular analysis of cells without the use of complex microfluidic instrumentation. Fluent's technology expands accessibility of single cell, molecule, or protein analysis to every laboratory, enabling broad market access for all researchers in biotech, pharma, and academic centers.

Forma Therapeutics (NASDAQ:  FMTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.

Genalyte delivers rapid, actionable results to physicians through decentralized laboratory testing, backed by remote Telehealth oversight and monitoring.

Graphite Bio (NASDAQ: GRPH) is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases.

Instil Bio, Inc. (NASDAQ: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer.

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry.

IO Biotech is a clinical-stage biopharmaceutical company pioneering the discovery and development of novel and highly differentiated immune-oncology therapeutics based on its proprietary technology platform, T-win®, which enables the activation of T cells that specifically target the immuno-suppressive tumor microenvironment.

Ionpath, Inc. has developed a mass spectrometry based imaging platform that permits 50+ biomolecules (proteins, DNA, RNA) to be measured simultaneously on a single tissue selection with resolution surpassing light microscopy.

IVERIC bio (NASDAQ:  ISEE) is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.

Janux Therapeutics, Inc. (NASDAQ:  JANX) is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer.

Mineralys Therapeutics, Inc. is a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.

MiroBio developing novel, best-in-class therapeutics that bring significant benefits to patients suffering from a range of auto-immune diseases.

Nalo, Inc. has a description that is just a placeholder for now. Then innovate products and services to improve the lives of patients suffering diseases.

Neurogene, Inc. is accelerating development of new genetic medicines to people with devastating neurological diseases.

Nkarta Therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to the broad population of patients with a variety of hematologic and solid tumor malignancies.

Nura, AKA:  Proneurotech, is aspiring to develop disease modifying therapeutics to improve the lives of patient and families struggling with neurodegenerative disorders.

Odonate, Inc. (NASDAQ: ODT) is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer.

Omniox, Inc. is an IND-stage biotherapeutics company developing breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs.

OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs).

Palvella Therapeutics is a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments.

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.

Principia Biopharma, Inc. (NASDAQ: PRNB) is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.

Rain Therapeutics Inc. (NASDAQ:  RAIN) is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.  This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.

SpringWorks, Inc. (NASDAQ:  SWTX) is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.

Sutro Biopharma (NASDAQ: STRO) is a clinical stage company focusing primarily on next generation cancer and autoimmune therapeutics.

 Synthekine is a biotechnology company focused on discovery and developing best in class cytokine therapeutics.

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is advancing a new wave of medicines to control the expression of disease-driving genes.

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.

Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging mutation agnostic technology and novel AAV capsids to restore vision in all patients with vision loss due to photoreceptor cell death.

Velicept Therapeutics, Inc. is a clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs.